Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Update

Intensity Therapeutics Inc. (NASDAQ:INTS) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 48,911 shares, a decline of 40.2% from the August 15th total of 81,764 shares. Currently, 1.6% of the company’s shares are sold short. Based on an average trading volume of 45,186 shares, the days-to-cover ratio is currently 1.1 days.

Analyst Upgrades and Downgrades

INTS has been the topic of several recent research reports. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. HC Wainwright boosted their price target on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. Finally, Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Intensity Therapeutics Stock Performance

Shares of NASDAQ:INTS remained flat at $3.81 during trading on Wednesday. The stock had a trading volume of 8,247 shares, compared to its average volume of 41,632. The stock has a market capitalization of $12.42 million, a price-to-earnings ratio of -1.07 and a beta of 2.76. Intensity Therapeutics has a 52-week low of $3.51 and a 52-week high of $43.50. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $4.36 and its two-hundred day simple moving average is $4.93.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). On average, sell-side analysts predict that Intensity Therapeutics will post -2.64 earnings per share for the current fiscal year.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.